McNeil Consumer Healthcare Resolves U.S. Department of Justice Investigation

Fort Washington, PA (March 10, 2015) – McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. today announced an agreement with the U.S. Attorney's Office for the Eastern District of Pennsylvania and the U.S. Department of Justice to resolve a previously disclosed government investigation relating to the manufacturing of certain over-the-counter products at its Fort Washington, PA facility.

The investigation commenced after the company's voluntary recalls of various products which occurred between 2008 and 2010. The voluntary recalls were not undertaken because of health or safety risks to consumers. Under the resolution McNeil will enter a plea to a single misdemeanor violation of the Federal Food, Drug, and Cosmetic Act, and accepts responsibility for the inadequate filing of required documents during the manufacturing process and will pay a settlement of $25 million.

"This plea agreement fully and finally resolves the federal government's investigation, and closes a chapter on actions that led the company to review and significantly improve its procedures," said Carol Goodrich, a spokesperson for McNeil Consumer Healthcare. "McNeil has been implementing enhanced quality and oversight standards across its entire business to ensure we are best able to meet our commitment to consumers, patients and doctors who rely on our products."

In 2011 the company agreed to a Consent Decree with the U.S. Food and Drug Administration (FDA) regarding the operation of McNeil manufacturing facilities in Fort Washington and Lancaster, PA and Las Piedras, Puerto Rico. A third party Current Good Manufacturing Practices (cGMP) expert has submitted written certification to the FDA for the aforementioned manufacturing facilities after determining that all three sites are in conformity with applicable laws and regulations.
# # #
Media Contact:
Carol Goodrich
Mobile: (973) 615-4057

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.